Provided by Tiger Trade Technology Pte. Ltd.

NanoViricides

1.30
0.0000
Post-market: 1.30-0.0018-0.14%19:08 EDT
Volume:426.60K
Turnover:551.39K
Market Cap:33.15M
PE:-2.99
High:1.41
Open:1.36
Low:1.26
Close:1.30
52wk High:2.23
52wk Low:0.8500
Shares:25.50M
Float Shares:24.90M
Volume Ratio:0.76
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4355
EPS(LYR):-0.6263
ROE:-101.46%
ROA:-55.53%
PB:3.82
PE(LYR):-2.08

Loading ...

NanoViricides Sets President Anil Diwan Base Salary at $400,000 Under Extension Agreement

Reuters
·
Yesterday

NanoViricides ‘actively exploring’ additional required funding

TIPRANKS
·
Sep 29

NanoViricides reports FY26 EPS (41c) vs. (63c) last year

TIPRANKS
·
Sep 29

Nanoviricides Q4 EPS $(0.10), Inline

Benzinga Earnings
·
Sep 29

NanoViricides FY26 Net Loss Narrows 13% to $8.22 Million; Revenue Remains no Revenue

Reuters
·
Sep 29

NanoViricides Starts Phase II DRC Trial of Oral NV-387 Gummies in Bundibugyo Ebola Patients

Reuters
·
Sep 28

Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 24

NanoViricides begins Phase II trial of NV-387 in Monkeypox in DRC

TIPRANKS
·
Sep 23

NanoViricides Begins Phase II Trial of NV-387 Oral Gummies for Mpox in Congo

Reuters
·
Sep 23

NanoViricides Wins DRC Regulatory Clearance to Start Phase II NV-387 Ebola Trial

Reuters
·
Sep 08

NanoViricides provides updateon Measles Drug Treatment Program

TIPRANKS
·
Aug 31

NanoViricides Drafts Phase II Trial Protocol for NV-387 Measles Treatment

Reuters
·
Aug 31

NanoViricides registers to sell 2.52M shares of common stock for holders

TIPRANKS
·
Aug 22

NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’

TIPRANKS
·
Aug 18

NanoViricides Wins DRC Acorep Clearance for Phase II NV-387 Ebola Treatment Trial

Reuters
·
Aug 18

NanoViricides, Inc: Received Regulatory Approval for a Phase Ii Clinical Trial of Nv-387 Oral Gummies as a Treatment for Ebola in DR Congo

THOMSON REUTERS
·
Aug 10

NanoViricides Wins DRC Approval for Phase II Trial of NV-387 Oral Gummies for Ebola Treatment

Reuters
·
Aug 10

NanoViricides Announces $3.8 Million Registered Direct Offering

TIPRANKS
·
Jul 30

NanoViricides Issues Warrants Exercisable at Us$1.75 in Us$3.8 Million Registered Direct Offering

Reuters
·
Jul 30

NanoViricides Raises Financing for Trial of Ebola Treatment, Awaits Regulatory Approval in Congo

MT Newswires Live
·
Jul 28